Abstract
Most patients who receive epidermal growth factor receptor (EGFR) inhibitors develop a rash. To date, no effective palliative therapy has been developed for these rashes. This review describes the rationale behind N05C4, a placebo-controlled trial of sunscreen as an intervention to prevent EGFR inhibitor-related rash.
Original language | English (US) |
---|---|
Pages (from-to) | 198-202 |
Number of pages | 5 |
Journal | Supportive Cancer Therapy |
Volume | 4 |
Issue number | 4 |
DOIs | |
State | Published - Sep 2007 |
Keywords
- Prevention
- Squamous cell carcinoma
- Ultraviolet light
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Cancer Research